X0508 4 2026-02-17 0002012593 Rapport Therapeutics, Inc. RAPP 0002022087 Bredt David RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100 BOSTON MA 02110 false true false false Chief Scientific Officer true Common Stock 2026-02-17 4 S false 900 28.0211 D 394675 D Common Stock 2026-02-17 4 S false 5400 28.9497 D 389275 D Common Stock 2026-02-17 4 S false 2200 29.5944 D 387075 D Common Stock 2026-02-19 4 M false 6000 1.8 A 393075 D Stock Options (Right to Buy) 1.8 2026-02-19 4 M false 6000 0 D 2033-12-05 Common Stock 6000 88080 D These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction. 25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. /s/ Troy Ignelzi, Attorney-in-Fact 2026-02-19